Abstract:Glioblastoma multiforme (GBM) is the most common malignant primary brain cancer affecting the adult population. Median overall survival for GBM patients is poor (15 months), primarily due to high rates of tumour recurrence and the paucity of treatment options. Oncolytic virotherapy is a promising treatment alternative for GBM patients, where engineered viruses selectively infect and eradicate cancer cells by inducing cell lysis and eliciting robust anti-tumour immune response. In this study, we evaluated the oncolytic potency of live-attenuated vaccine strains of Zika virus (ZIKV-LAV) against human GBM cells in vitro. Our findings revealed that Axl and integrin α v β 5 function as cellular receptors mediating ZIKV-LAV infection in GBM cells. ZIKV-LAV strains productively infected and lysed human GBM cells but not primary endothelia and terminally differentiated neurons. Upon infection, ZIKV-LAV mediated GBM cell death via apoptosis and pyroptosis. This is the first in-depth molecular dissection of how oncolytic ZIKV infects and induces death in tumour cells.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the potential of the Zika virus live - attenuated vaccine strain (ZIKV - LAV) as an oncolytic virus for the treatment of human glioblastoma multiforme (GBM). Specifically, the study aims to evaluate the selective infectivity of the ZIKV - LAV strain for human GBM cells in vitro and the mechanism by which it induces cancer cell death. At the same time, it examines whether these virus strains will infect non - tumor cells (such as terminally differentiated neurons and primary endothelial cells) to evaluate their safety. ### Main research contents: 1. **Infectivity of ZIKV - LAV strain for GBM cells**: - The study found that the ZIKV - LAV strain can effectively infect and lyse three human GBM cell lines (DBTRG, LN18 and T98G), but has no obvious infectivity for normal human brain microvascular endothelial cells (HBMEC) and terminally differentiated neurons. - The replication kinetics of the ZIKV - LAV strain in GBM cells is similar to that of the wild - type ZIKV, indicating that it can fully replicate in cancer cells and produce new virus particles. 2. **Mechanism of cell death induced by ZIKV - LAV strain**: - Through a variety of experimental methods (such as fluorescence microscopy, immunofluorescence staining, cell viability detection, etc.), the study confirmed that after the ZIKV - LAV strain infects GBM cells, it can induce cell death through apoptotic (non - lytic) and lytic cell death (such as pyroptosis) pathways. - In particular, the activation of the pyroptosis pathway, manifested as the cleavage of Gasdermin - D (GSDMD) and the increased secretion of IL - 1β, may help to enhance the anti - tumor immune response. 3. **Cell receptors of ZIKV - LAV strain**: - Through siRNA - mediated gene knockdown experiments, the study determined that Axl and integrin αvβ5 are the main receptors for the ZIKV - LAV strain to infect GBM cells. - The expression levels of Axl and integrin αvβ5 vary in different GBM cell lines, which may be the reason for the different infectivity of the ZIKV - LAV strain in different cell lines. ### Conclusions: - The ZIKV - LAV strain has significant oncolytic activity against human GBM cells in vitro and can selectively infect cancer cells without affecting normal cells, showing good safety and therapeutic potential. - The ZIKV - LAV strain enters GBM cells through Axl and integrin αvβ5 receptors and induces cancer cell death through multiple cell death pathways (including apoptosis and pyroptosis), which may help to enhance the anti - tumor immune response. - These findings provide an important molecular mechanism basis for further developing the ZIKV - LAV strain as a new oncolytic virus for GBM treatment.

Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells

Zika Virus Has Oncolytic Activity Against Glioblastoma Stem Cells

Transduction Efficiency of Zika Virus E Protein Pseudotyped HIV-1gfp and Its Oncolytic Activity Tested in Primary Glioblastoma Cell Cultures

Zika Virus Oncolytic Activity Requires Cd8(+) T Cells And Is Boosted By Immune Checkpoint Blockade

Oncolytic Zika Virus Promotes Intratumoral T Cell Infiltration and Improves Immunotherapy Efficacy in Glioblastoma

Zika Virus: A Neurotropic Warrior against High-Grade Gliomas—Unveiling Its Potential for Oncolytic Virotherapy

Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin αvβ5 Axis

Gospel of malignant Glioma: Oncolytic virus therapy

Differential Replication and Oncolytic Effects of Zika Virus in Aggressive CNS Tumor Cells: Insights from Organoid and Tumoroid Models

Transcriptomic Meta-analysis Identifies Long Non-Coding RNAs Mediating Zika's Oncolytic Impact in Glioblastoma Multiforme

Breaking Barriers: A Future Perspective on Glioblastoma Therapy with mRNA-Based Immunotherapies and Oncolytic Viruses

Integrated re-analysis of transcriptomic and proteomic datasets reveals potential mechanisms for Zika viral-based oncolytic therapy in neuroblastoma

Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity

A Virus-Mimicking Nucleic Acid Nanogel Reprograms Microglia and Macrophages for Glioblastoma Therapy.

Cell Membrane-Coated Oncolytic Adenovirus for Targeted Treatment of Glioblastoma

Zika virus-based immunotherapy enhances long-term survival of rodents with brain tumors through upregulation of memory T-cells

Genetically modified ZIKA virus as a microRNA-sensitive oncolytic virus against central nervous system tumors

EXTH-77. TARGETING CD73 IN GBM SENSITIZES TUMORS TO ONCOLYTIC VIRUS THERAPY

An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma

An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma

Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy